Cyteir Therapeutics Inc

NASDAQ CYT

Data sourced from

and

Download Data

Cyteir Therapeutics Inc Tangible Asset Value Ratio for the quarter ending September 30, 2023

Cyteir Therapeutics Inc Tangible Asset Value Ratio is NA for the quarter ending September 30, 2023. The tangible asset value ratio measures the proportion of tangible assets to total assets. It is calculated by dividing the tangible assets by the total assets. This ratio indicates the significance of tangible assets, such as property, plant, and equipment, in the company's total asset structure. A higher ratio suggests a higher proportion of tangible assets relative to total assets.

Cyteir Therapeutics Inc Tangible Asset Value Ratio for the quarter ending September 30, 2022 was 0.95, a -0.76% change year over year.
Cyteir Therapeutics Inc Tangible Asset Value Ratio for the quarter ending September 30, 2021 was 0.96.

NASDAQ: CYT

Cyteir Therapeutics Inc

CEO	Mr. Joseph S. Zakrzewski
IPO Date	June 18, 2021
Location	United States
Headquarters	128 Spring Street, Lexington, MA, United States, 02421
Employees	46
Sector	Healthcare
Industry	Biotechnology

Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Key trends